Best Psychedelic Stocks to Buy in 2026 and How to Invest

Whether you call them magic mushroom stocks, 'shroom stocks, or psilocybin stocks, psychedelic stocks are hot right now. Psychedelics have gone from a countercultural fad of the 1960s to mainstream medicine in the 2020s.

Quite a few psychedelic pharmaceutical companies are developing drugs that follow the legal, regulatory pathway to approval. Hallucinogens, including psilocybin, are showing considerable promise in treating illnesses such as depression and schizophrenia. Let's explore five of the best publicly traded psychedelic companies on the market today.

Five top psychedelic stocks for 2026

Psychedelic stocks are simply healthcare stocks focused on the use of hallucinogens to treat diseases. Because the area is still fairly new, most of these companies have relatively low market capitalizations. However, many are growing rapidly.

Here are five of the top psychedelic stocks.

1. AtaiBeckley

Benefits and risks of investing in psychedelic stocks

The benefits of investing in psychedelic stocks include:

• Significant long-term growth potential.
• An opportunity to get in early on a nascent market.
• A way to participate in novel treatments that help patients with neurological and psychological disorders.

However, there are also risks associated with investing in psychedelic stocks, including:

• High volatility
• Risk of clinical failures
• Risk of regulatory setbacks

Should you invest in psychedelic stocks?

Investors who are risk-averse should probably avoid psychedelic stocks because of their volatility and potential for clinical failures and regulatory setbacks. Income investors should also look elsewhere because no psychedelic stock currently pays dividends.

On the other hand, aggressive investors who aren't afraid to take on considerable risk could find some psychedelic stocks attractive. Investors who like to get in on the ground floor of an emerging market may also want to consider buying psychedelic stocks.

FAQ